Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
Go back to Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial| (NASDAQ: PLRZ) | Delayed: 15.31 +0.92 (6.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.39 | 52 Week High | $ | |||
| Open | $14.39 | 52 Week Low | $ | |||
| Day High | $15.31 | P/E | N/A | |||
| Day Low | $13.59 | EPS | $ | |||
| Volume | 92,925 | |||||

